Biotechnology Sanctions Law In Ukraine.
1. Introduction
Biotechnology Sanctions Law in Ukraine refers to the legal framework governing the use of economic, financial, trade, scientific, technological and diplomatic sanctions against individuals, companies, research institutions and foreign organisations involved in biotechnology-related activities.
Ukraine's biotechnology sanctions framework is particularly important because of the armed conflict with Russia, national-security concerns, restrictions on dual-use technologies, biological research security, pharmaceutical supply chains and international export-control obligations.
Unlike a separate biotechnology sanctions statute, Ukraine primarily regulates these matters through its general sanctions legislation, export-control laws, pharmaceutical regulations, criminal law and international sanctions commitments.
The central objective is to prevent biotechnology, genetic engineering, biological materials, laboratory equipment and pharmaceutical technologies from being used to support military aggression, prohibited proliferation or activities threatening national security.
2. Legal Framework Governing Biotechnology Sanctions
The principal legislation includes the following:
A. Law of Ukraine on Sanctions, 2014
The Law of Ukraine On Sanctions, No. 1644-VII of 14 August 2014, is the central legal instrument.
It authorises restrictive measures against foreign states, foreign legal entities, individuals and other designated persons whose activities threaten Ukraine's national interests, security, sovereignty or territorial integrity.
Potentially relevant measures include:
Blocking assets and financial transactions.
Restrictions on trade and economic activities.
Suspension of licences and permits.
Restrictions on technology transfers.
Prohibition of certain commercial operations.
Restrictions on scientific and technical cooperation.
Other measures authorised by Ukrainian law.
For biotechnology businesses, these restrictions may affect laboratory equipment, pharmaceutical manufacturing, genetic research materials, research contracts and international investment.
B. Law on Foreign Economic Activity, 1991
This legislation establishes the framework for Ukraine's international trade and foreign economic relations.
Biotechnology exporters and importers must consider applicable trade restrictions, special sanctions, licensing requirements and prohibitions when conducting international transactions.
C. Law on State Control over International Transfers of Military and Dual-Use Goods, 2003
This law is especially important for biotechnology.
Certain biological materials, laboratory equipment, genetic engineering technologies and related technical information may fall within dual-use export-control classifications.
Consequently, a biotechnology company cannot assume that a product is freely exportable merely because it is intended for medical or scientific research.
D. Law on Medicinal Products
Ukraine's pharmaceutical regulatory framework governs medicinal-product authorisation, manufacturing, quality standards and distribution.
Where sanctions affect pharmaceutical manufacturers, suppliers or beneficial owners, the relevant regulatory and sanctions restrictions must be considered together.
E. Criminal Code of Ukraine
Criminal liability may arise where conduct connected with prohibited transactions also constitutes an offence under Ukrainian criminal law, including offences involving national security, financing prohibited activities, illegal trafficking or violations of applicable export-control requirements.
3. Biotechnology Activities That May Be Affected by Sanctions
Ukraine's sanctions framework can affect several biotechnology sectors.
| Biotechnology sector | Potential sanctions implications |
|---|---|
| Genetic engineering | Restrictions on technology transfers and sanctioned research partners |
| Pharmaceutical biotechnology | Restrictions on manufacturers, suppliers and financial transactions |
| Vaccine development | Restrictions affecting sanctioned entities and controlled materials |
| Synthetic biology | Export-control restrictions on relevant dual-use technologies |
| Genomic research | Restrictions on cooperation with designated institutions |
| Biological laboratories | Restrictions on equipment, materials and technical assistance |
| Agricultural biotechnology | Trade restrictions and GMO-related regulatory controls |
| Biopharmaceutical manufacturing | Restrictions on investment, procurement and supply agreements |
| Biological sample exchange | Restrictions on transactions involving designated persons or prohibited goods |
An important distinction is that sanctions do not automatically prohibit every biotechnology activity involving Russia, Belarus or another restricted jurisdiction. The applicable designation, transaction, ownership relationship, goods classification and specific legal prohibition must be examined.
4. Sanctions Against Biotechnology Companies and Research Institutions
Under the 2014 Sanctions Law, Ukrainian authorities can impose restrictive measures against qualifying foreign entities and individuals.
For biotechnology companies, sanctions screening should examine:
The company's legal identity and registered ownership.
Its beneficial owners and controlling persons.
Whether it appears in Ukraine's State Register of Sanctions.
Whether its shareholders or business partners are designated.
Whether the proposed transaction involves restricted goods or technologies.
Whether payments or contractual obligations are prohibited.
For example, consider a Ukrainian biotechnology company entering into a research agreement with a foreign laboratory.
If the laboratory is subject to applicable asset-blocking sanctions, the Ukrainian company must determine whether transferring research funds, equipment, genetic materials or other economic resources would violate the relevant restrictions.
A transaction cannot be considered lawful simply because the agreement describes its purpose as medical research.
5. Export Controls on Biological Materials and Dual-Use Technologies
The Law on State Control over International Transfers of Military and Dual-Use Commodities, No. 549-IV of 20 February 2003, is particularly significant.
It regulates international transfers of controlled goods, technologies and related technical assistance.
Biotechnology products may become subject to export-control requirements when they have potential military, biological-security or proliferation applications.
Examples include:
Certain biological agents and toxins.
Specialised laboratory equipment.
Certain genetic engineering technologies.
Controlled biological production equipment.
Technical information associated with controlled items.
Materials and equipment capable of supporting prohibited biological activities.
The legal classification depends on the applicable control lists and technical specifications.
Illustration: A Ukrainian laboratory intends to export specialised biological research equipment to a foreign research institution. If the equipment falls within a controlled category, the exporter may need authorisation from the competent Ukrainian export-control authority.
A sanctions designation may create an additional prohibition, even where an export licence would otherwise be available.
The export-control law was amended in 2025, and its official consolidated text should be consulted when assessing a current transaction.
zakon.rada.gov.ua+1
6. Pharmaceutical Biotechnology and Sanctions Compliance
Pharmaceutical biotechnology is especially sensitive because sanctions can affect medicines, vaccines, biological manufacturing systems and international supply chains.
Relevant activities include:
Importing biological medicines.
Manufacturing recombinant proteins.
Developing monoclonal antibodies.
Producing vaccines.
Importing laboratory reagents.
Transferring pharmaceutical manufacturing technology.
Conducting clinical research with foreign institutions.
The Law on Medicinal Products, No. 123/96-VR, provides the domestic pharmaceutical regulatory framework.
Sanctions compliance and pharmaceutical authorisation are separate legal questions.
For example, a medicine may have valid regulatory authorisation but its importation or payment may still be affected by a specific sanctions restriction.
Conversely, the fact that a foreign pharmaceutical company is not sanctioned does not automatically establish that its products satisfy Ukrainian registration, quality or import requirements.
7. Biological Safety and Genetically Modified Organisms
Ukraine's Law No. 1103-V of 31 May 2007, concerning the state system of biosafety in the creation, testing, transportation and use of genetically modified organisms, is another important component.
This law addresses biosafety rather than sanctions directly.
Nevertheless, it becomes relevant when sanctions affect international biotechnology transfers involving:
Genetically modified organisms.
Biological research materials.
GMO testing and transportation.
Agricultural biotechnology.
Research involving biological containment.
International cooperation in genetic engineering.
The regulatory authorities must distinguish between an ordinary biosafety violation and a sanctions violation.
A company may comply with GMO safety requirements but still breach sanctions or export-control restrictions through an unlawful international transaction.
zakon.rada.gov.ua+1
8. Enforcement and Legal Consequences
The consequences of sanctions violations depend on the applicable legislation and the particular conduct.
Potential consequences include:
A. Asset blocking
A designated company's funds, bank accounts and other assets may be frozen under the applicable sanctions decision.
B. Suspension or cancellation of licences
Relevant permits and authorisations may be suspended or cancelled where the legal requirements for doing so are satisfied.
C. Trade restrictions
Transactions involving prohibited goods, designated entities or restricted economic activities may be stopped.
D. Contractual consequences
A sanctions prohibition may prevent the lawful performance of an international research, manufacturing or distribution agreement.
E. Criminal liability
Where the conduct independently satisfies the elements of a criminal offence, the Criminal Code may apply. Sanctions designation alone should not be treated as automatic proof of criminal guilt.
F. State confiscation of assets
Article 4 of the Sanctions Law provides for recovery of qualifying assets into state ownership as a separate sanctions measure. Article 5-1 establishes the relevant conditions. This exceptional measure should not be confused with an ordinary temporary asset freeze.
on August 14, 2014 № 1644-VII+1
9. Important Case Laws and Judicial Decisions
There is an important distinction between cases directly concerning biotechnology sanctions and cases establishing general principles governing Ukrainian sanctions. The following decisions are relevant to biotechnology businesses because they address asset freezes, proportionality, procedural fairness and judicial review.
Case 1. M.S.L., TOV v. Ukraine (2025)
Particularly important
Court: European Court of Human Rights.
Application No.: 18049/18.
Decision date: 16 October 2025.
Legal provisions: Article 1 of Protocol No. 1 and Article 13 of the European Convention on Human Rights.
Facts:
The applicant company challenged economic restrictions imposed under Ukraine's Sanctions Law. Its assets had been frozen through decisions of the Ukrainian authorities.
The company argued that the restrictions interfered with its property rights and that it lacked an effective remedy.
Judgment:
The European Court of Human Rights found violations concerning the freezing of assets and the absence of sufficient procedural safeguards against arbitrariness.
The Court particularly considered:
Insufficient individualised justification for the restrictions.
Inadequate procedural safeguards.
Limitations in judicial review.
The absence of an effective remedy.
Importance for biotechnology law:
Suppose a biotechnology company has its laboratory assets, pharmaceutical funds or research infrastructure frozen under Ukrainian sanctions legislation.
This judgment establishes an important principle: national-security objectives do not eliminate the requirement for lawful, sufficiently justified and procedurally fair sanctions.
A biotechnology company should have a meaningful opportunity to challenge restrictions affecting its property.
HUDOC+2
Case 2. Supreme Court of Ukraine, Case No. 805/430/18-a (2021)
Court: Supreme Court of Ukraine.
Decision date: 31 March 2021.
Proceeding No.: K/9901/58687/18.
Legal principles:
The Supreme Court discussed the requirements governing administrative sanctions.
It emphasised that administrative sanctions must:
Have a legal basis.
Be proportionate to the actual violation.
Be imposed within a reasonable period.
Respect procedural fairness and the right to a fair hearing.
Importance for biotechnology law:
Where a biotechnology enterprise faces suspension of its regulatory authorisation or other restrictive administrative measures, these principles support the requirement for a lawful and proportionate decision.
The case is relevant by analogy; it is not a biotechnology-specific sanctions judgment.
supreme.court.gov.ua
Case 3. Yanukovych v. Council of the European Union (2023)
Court: General Court of the European Union.
Cases: T-263/21 and T-257/22.
Decision date: 20 December 2023.
Facts:
The cases concerned restrictive measures against Oleksandr Yanukovych, including the freezing of funds in connection with alleged misappropriation of Ukrainian state funds.
Judgment and legal principles:
The General Court examined the Council's obligation to verify whether decisions by third-country authorities respected fundamental procedural rights, including the rights of defence and effective judicial protection.
Importance for biotechnology law:
The principle is relevant when Ukrainian biotechnology companies or research institutions face foreign sanctions based on information supplied by another jurisdiction.
Sanctions authorities must consider the reliability and procedural legitimacy of the underlying material.
EUR-Lex
Case 4. Fridman and Others v. Council (2024)
Court: General Court of the European Union.
Case: T-635/22.
Decision date: 11 September 2024.
Facts:
The proceedings concerned restrictive measures, asset freezing, reporting obligations and alleged circumvention of sanctions.
Legal significance:
The judgment examined the legality of restrictive measures, the Council's powers and proportionality.
Importance for biotechnology law:
A biotechnology company cannot avoid applicable restrictions simply by transferring ownership, changing intermediaries or using another company to conduct a prohibited transaction.
Corporate restructuring and beneficial ownership must therefore be examined carefully.
Cour de justice de l’Union européenne+1
Case 5. Igor Shuvalov v. Council of the European Union (2025)
Court: Court of Justice of the European Union.
Case: C-271/24 P.
Decision date: 13 March 2025.
Facts:
The case concerned restrictive measures adopted in response to actions threatening Ukraine's territorial integrity, sovereignty and independence.
Legal significance:
The proceedings addressed the legal basis for listing an individual under the EU sanctions framework and the assessment of supporting actions or policies.
Importance for biotechnology law:
This decision is relevant when assessing whether foreign investors, corporate controllers or business partners involved in biotechnology transactions may become subject to international sanctions.
It is an EU sanctions decision, not a ruling on Ukraine's domestic biotechnology legislation.
EUR-Lex
10. Constitutional and Human Rights Considerations
Biotechnology sanctions must operate consistently with applicable constitutional and human-rights protections.
The relevant principles include:
1. Property rights: Article 41 of the Constitution of Ukraine protects property rights, subject to lawful limitations.
2. Equality before the law: Article 24 protects equality and prohibits unjustified discrimination.
3. Judicial protection: Article 55 guarantees the right to judicial protection.
4. Right to health: Article 49 recognises the right to health protection and medical assistance.
5. Due process: Article 62 protects the presumption of innocence in criminal proceedings.
These provisions are important where sanctions affect pharmaceutical distribution, medical research, biological laboratories or access to essential medicines.
For instance, sanctions affecting a pharmaceutical supplier should be implemented with attention to the applicable restrictions and the consequences for lawful medical supply chains.
11. International Cooperation and Foreign Sanctions
Ukraine's biotechnology sanctions framework operates alongside international sanctions and export-control systems.
Important international instruments and frameworks include:
UN Security Council sanctions: Relevant binding sanctions measures adopted under the UN Charter.
European Union sanctions: EU restrictive measures affecting designated individuals, entities and transactions.
Wassenaar Arrangement: Relevant controls concerning certain dual-use goods and technologies.
Biological Weapons Convention, 1972: Prohibits the development, production, acquisition and stockpiling of biological and toxin weapons.
Chemical Weapons Convention, 1993: Relevant where biotechnology operations involve controlled chemical substances.
Cartagena Protocol on Biosafety: Relevant to the safe transfer, handling and use of living modified organisms.
These frameworks have different legal effects. For example, EU sanctions do not automatically become Ukrainian domestic sanctions merely because Ukraine aligns its policies with the EU.
12. Compliance Obligations for Biotechnology Companies
Biotechnology enterprises operating in Ukraine or conducting international business with Ukrainian partners should establish a sanctions-compliance programme.
The essential elements include:
1. Sanctions screening: Check customers, suppliers, investors and research partners against applicable sanctions lists.
2. Ownership verification: Identify ultimate beneficial owners and persons exercising direct or indirect control.
3. Export-control assessment: Classify biological materials, laboratory equipment and technical information.
4. Transaction monitoring: Examine payments, transfers, financing and contractual arrangements.
5. Research collaboration review: Verify the legal status of foreign universities, laboratories and research institutions.
6. Contractual safeguards: Include sanctions representations, notification duties, suspension clauses and termination provisions.
7. Record keeping: Maintain licences, screening records, export documentation and transaction evidence.
8. Regulatory reporting: Cooperate with competent Ukrainian authorities when legally required.
9. Humanitarian safeguards: Assess applicable exemptions and authorisations for essential medicines and medical supplies.
10. Periodic review: Reassess sanctions exposure when legislation, sanctions lists or ownership arrangements change.
13. Hypothetical Legal Case Study
Situation:
A Ukrainian biotechnology company enters into a contract with a foreign pharmaceutical research institution to develop a vaccine.
The foreign institution subsequently becomes subject to Ukrainian asset-blocking sanctions.
The Ukrainian company has already transferred research funding and laboratory equipment.
Legal questions:
Can the company continue the research collaboration?
Can it transfer additional payments?
Can it recover previously transferred equipment?
Does the foreign institution's designation affect its subsidiaries?
Can the company challenge the sanctions decision?
Legal analysis:
First, the company must identify the exact sanctions imposed and the institution's ownership and control structure.
Second, it must determine whether further payments, equipment transfers or contractual performance are prohibited.
Third, it should examine whether any applicable exemption or authorisation is available.
Fourth, the company must preserve documentation concerning the transaction and obtain appropriate legal advice before making further transfers.
Finally, if the company or its assets are directly affected by an unlawful sanctions decision, it may consider judicial remedies under Ukrainian law and applicable human-rights protections.
The M.S.L., TOV v. Ukraine judgment is particularly relevant to the procedural safeguards involved.
14. Major Legal Challenges
Ukraine's biotechnology sanctions framework faces several important legal challenges.
| Legal challenge | Main concern |
|---|---|
| Scientific cooperation | Distinguishing legitimate research from prohibited assistance |
| Pharmaceutical supply | Maintaining access to essential medicines |
| Dual-use technologies | Identifying military and civilian applications |
| Ownership structures | Detecting indirect control by designated persons |
| International transfers | Coordinating multiple jurisdictions |
| Research funding | Preventing prohibited financial transfers |
| Human rights | Ensuring proportionate sanctions |
| Judicial remedies | Providing effective review of sanctions decisions |
| Biological security | Preventing misuse of biological research |
| Regulatory coordination | Harmonising sanctions, biosafety and pharmaceutical requirements |
15. Conclusion
Biotechnology Sanctions Law in Ukraine is an intersection of national-security legislation, international trade controls, pharmaceutical regulation, biological safety and human-rights law.
The Law on Sanctions, 2014, provides the principal legal foundation. The Dual-Use Goods Control Law, 2003, and GMO Biosafety Law, 2007, provide additional regulatory safeguards for biotechnology-related activities.
The most important judicial development is M.S.L., TOV v. Ukraine (2025), which demonstrates that sanctions must be accompanied by adequate procedural safeguards, individualised justification and effective judicial remedies.
The central legal principle is that biotechnology activities must comply with applicable sanctions and export-control restrictions without abandoning the requirements of legality, proportionality, scientific safety and human-rights protection.
16. Important Primary Legal Sources
Law of Ukraine on Sanctions, No. 1644-VII (2014).
Ukrainian legislation on GMO biosafety and medicinal products.
M.S.L., TOV v. Ukraine (2025), European Court of Human Rights.
Supreme Court of Ukraine, Case No. 805/430/18-a (2021).
Research note: This is a general academic legal explanation, not an opinion on a particular transaction. The cited cases establish general sanctions and procedural principles; they should not be represented as direct biotechnology-sanctions precedents. The consolidated legislation and applicable sanctions lists should be checked before relying on the analysis in 2026.

comments